eligibility_summary
Eligible: females 25-70 who are candidates for neoadjuvant therapy (per 2023 CSCO), treatment-naive, using allowed regimens (TNBC: T-EC±anti-PD-1, HER2+: EC-THP/HP, HR+/HER2-: AI±CDK4/6i), with obtainable tumor tissue and full pathology. Exclude: no consent/specimens, severe illness, prior systemic/radiation, ineligible regimen/indication, or investigator judgment. Withdrawal: subject choice, loss to follow-up, or safety/progression/compliance per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Neoadjuvant regimens by subtype and mechanisms: TNBC: T-EC chemotherapy (taxane + epirubicin + cyclophosphamide) ± anti–PD-1, or anti–PD-1 alone. Mechanisms: taxane = microtubule-stabilizing cytotoxic, epirubicin (anthracycline) = Topo II inhibition/DNA intercalation, cyclophosphamide = DNA alkylator, anti–PD-1 (checkpoint monoclonal antibody) blocks PD-1 to reinvigorate T cells. HER2+HR−: EC-THP (EC chemo + taxane + trastuzumab + pertuzumab) or HP (trastuzumab+pertuzumab). Mechanisms: trastuzumab (anti-HER2 mAb) inhibits HER2 signaling/mediates ADCC, pertuzumab (anti-HER2 mAb) blocks HER2 dimerization, taxane as above. HER2−HR+: aromatase inhibitor ± CDK4/6 inhibitor, AIs reduce estrogen synthesis, CDK4/6 inhibitors arrest G1–S via RB. Targeted cells/pathways: tumor epithelial cells (HER2/ERBB, ER signaling, CDK4/6–RB, mitotic spindle, DNA damage/repair) and immune microenvironment (PD-1/PD-L1 axis, CD8+ T cells, NK/ADCC). Single-cell and spatial transcriptomics profile responders vs. resistant.